agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma

Summary

This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants with relapsed or refractory multiple myeloma, as well as to define the recommended Phase 2 dose.

Timeline

Start

2021-03-29

Primary completion

2023-01-13

Completion

2023-05-31

Drugs

Indications